Nuritas key facts
as of Oct 2026- Developer of a biotechnology platform designed to extract peptides from food sources.
- Nuritas is valued at approximately $384.9M as of Oct 2026 (last reported valuation).
- It has raised $149.7M; the latest was Accelerator/Incubator in Jul 2025.
- Notable investors include Enterprise Ireland, Keiretsu Forum, Builders VC, SVG Ventures|THRIVE, NDRC — 29 tracked in total.
- Status: Privately Held (backing).
Nuritas's last reported valuation, Nov 2021. Nothing priced has surfaced since.
- ·The complete investor list: 29 names
- ·Watch Nuritas: the Monday email on marks, rounds and moves
Nuritas funding rounds
No funding rounds for Nuritas are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Nuritas
29+Membership and data by Private Market View
Nuritas valuation
Nuritas's last reported valuation was $385 million in Nov 2021. No priced round, secondary trade or fund mark has surfaced since.
Nuritas investors
29 investors are on record for Nuritas, including Enterprise Ireland, Keiretsu Forum, Builders VC and SVG Ventures|THRIVE.
About Nuritas
Developer of a biotechnology platform designed to extract peptides from food sources. The company's platform combines artificial intelligence and genomics to discover and unlock natural bioactive peptides with health benefits, enabling businesses to make the food system more sustainable by replacing unwanted ingredients and molecules with more natural and sustainable ones.
- Sector
- Healthcare
- HQ
- Dublin, Ireland
- Founded
- 2014
- Employees
- 60
- Website
- nuritas.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.